Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

895
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
895
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

115
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
115
Management of Insomnia01:19

Management of Insomnia

760
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
760
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

651
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
651

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study.

Dermatology and therapy·2026
Same author

Intersectional inequalities in somatic symptom severity: A trans-diagnostic MAIHDA analysis of SOMACROSS data.

Journal of psychosomatic research·2026
Same author

Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.

Acta dermato-venereologica·2026
Same author

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin - data from the SOMA.PRU study.

Frontiers in immunology·2026
Same author

Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study.

The British journal of dermatology·2026
Same author

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Related Experiment Video

Updated: Mar 15, 2026

Development of Metarhizium anisopliae as a Mycoinsecticide: From Isolation to Field Performance
14:15

Development of Metarhizium anisopliae as a Mycoinsecticide: From Isolation to Field Performance

Published on: July 30, 2017

21.6K

Itch Management: Treatments under Development.

Manuel Pedro Pereira, Sonja Ständer

    Current Problems in Dermatology
    |September 1, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Novel drugs targeting complex mechanisms of pruritus are in development for conditions like inflammatory dermatoses and uremic pruritus. Further research and clinical trials are crucial for effective chronic pruritus treatments.

    More Related Videos

    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
    06:47

    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

    Published on: December 5, 2020

    7.5K
    Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe
    06:16

    Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe

    Published on: March 1, 2022

    4.7K

    Related Experiment Videos

    Last Updated: Mar 15, 2026

    Development of Metarhizium anisopliae as a Mycoinsecticide: From Isolation to Field Performance
    14:15

    Development of Metarhizium anisopliae as a Mycoinsecticide: From Isolation to Field Performance

    Published on: July 30, 2017

    21.6K
    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
    06:47

    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

    Published on: December 5, 2020

    7.5K
    Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe
    06:16

    Mistletoe Eradicator - A Novel Tool for Simultaneous Mechanical and Chemical Control of Mistletoe

    Published on: March 1, 2022

    4.7K

    Area of Science:

    • Dermatology
    • Neurology
    • Pharmacology

    Background:

    • Pruritus, or itching, stems from diverse dermatological, neurological, and systemic issues.
    • The complex mechanisms of acute and chronic pruritus transmission are not fully understood.
    • Recent advancements have improved understanding, leading to the development of new therapeutic agents.

    Purpose of the Study:

    • To provide an overview of drugs under development for pruritus.
    • To highlight the pathophysiological mechanisms targeted by these novel therapies.
    • To emphasize the need for continued research and clinical trials, especially for specific patient groups.

    Main Methods:

    • Review of ongoing randomized clinical trials for novel pruritus therapies.
    • Identification of drug compounds targeting specific molecular pathways.
    • Analysis of unmet needs in chronic pruritus treatment.

    Main Results:

    • Several novel drug classes are in development, including neurokinin 1 receptor antagonists, anti-interleukin-31 receptor A antibodies, and κ-opioid agonists.
    • These compounds target key pathways implicated in inflammatory dermatoses, uremic pruritus, cholestatic pruritus, cutaneous T-cell lymphoma, and prurigo nodularis.
    • Despite progress, effective treatments for chronic pruritus remain insufficient.

    Conclusions:

    • New therapies show promise for various pruritus types by targeting specific pathophysiological mechanisms.
    • Further basic research and clinical trials are essential to address the unmet needs in chronic pruritus management.
    • Specialized trials for populations like pregnant women and children are critical due to limited approved options.